OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
DAAP appoints Joseph Heathcott as new associate dean for research
August 27, 2026
DAAP appoints new associate dean for research Joseph Heathcott, who will bring a nationally recognized voice in urban development, design and research to the University of Cincinnati starting this fall 2026.
UC, NKU renew longstanding partnership supporting Army ROTC cadets
August 26, 2026
The University of Cincinnati Army ROTC and Northern Kentucky University (NKU) have renewed a longstanding partnership that supports students preparing to become Army officers and leaders in their communities. The universities formalized the renewed agreement during a signing event Aug. 11 at NKU.
Funding expands UC research into weight gain side effects of bipolar medication
August 26, 2026
University of Cincinnati researchers have been approved for funding by the Patient-Centered Outcomes Research Institute (PCORI) to expand the implementation of healthy lifestyle interventions and metformin prescription to help manage weight gain in overweight or obese youth taking second-generation antipsychotic medications.